GA
NVO

Geneva Advisors’s Novo Nordisk NVO Stock Holding History

Geneva Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-94,348
Closed -$2.54M – 763
2016
Q2 		$2.54M Sell
94,348
-9,318
-9% -$256K 0.05% 169
2016
Q1 		$2.81M Sell
103,666
-14,080
-12% -$377K 0.06% 146
2015
Q4 		$3.42M Sell
117,746
-2,356
-2% -$65.2K 0.07% 136
2015
Q3 		$3.26M Sell
120,102
-6,268
-5% -$177K 0.07% 145
2015
Q2 		$3.46M Sell
126,370
-34,156
-21% -$960K 0.06% 153
2015
Q1 		$4.29M Buy
160,526
+31,500
+24% +$725K 0.08% 140
2014
Q4 		$2.73M Sell
129,026
-44,810
-26% -$1M 0.05% 170
2014
Q3 		$4.14M Buy
173,836
+57,488
+49% +$1.32M 0.08% 139
2014
Q2 		$2.69M Buy
+116,348
New +$2.57M 0.05% 182

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Geneva Advisors's NVO Position: Q3 2016 in Review

Geneva Advisors sold out of Novo Nordisk (NVO) in Q3 2016, closing a stake of 94,348 shares — an estimated $2.54M sold.

Geneva Advisors first reported a position in NVO in Q2 2014 and held it in 9 quarters. The position peaked at $4.29M in Q1 2015. 513 funds tracked by Wall St. Rank hold NVO as of Q3 2016.

  • Geneva Advisors reported no remaining Novo Nordisk position as of Q3 2016 after selling out during the quarter.
  • Geneva Advisors sold 94,348 Novo Nordisk shares in Q3 2016, an estimated $2.54M.
  • Geneva Advisors first reported a position in Novo Nordisk in Q2 2014 and held it in 9 quarters.
  • Geneva Advisors's Novo Nordisk position peaked at $4.29M in Q1 2015.
  • 513 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2016.

Based on Geneva Advisors's 13F filing for Q3 2016, filed 9 Nov 2016.